Clinical Development

This starts at the very beginning, where the advantages of our transgenic platforms ensure that we can avoid many of the late stage failures inherent to other platforms, such as the immunogenicity of CDR-grafting¹ or the nearly fivefold higher levels of development ‘red flags’ in antibodies from phage display platforms². Development considerations are then incorporated at every step of early discovery, ensuring we only advance candidates with the greatest possible likelihood of clinical success. It is through this close working relationship between the discovery and development teams, as well as within PetMedix more broadly, that we will develop the very best veterinary medicines.